Bordeaux, Boston, February 2, 2015 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible),a medical technology company specializing in vertebral and knee-surgery implants, today
announces that it has been definitively granted intellectual protection for its JAZZ technology in Europe until 2031 (under patent number EP 2521500).
A major milestone regarding the continuation of the Company’s innovation strategy, this patent applies to the entire JAZZ system and definitively secures full protection of the implant’s technical characteristics.
Ludovic Lastennet, CEO of Implanet, says: “This announcement validates the excellent upstream work accomplished by our Research and Development team to put in place long-term barriers to entry, by significantly reducing any possible attempts to develop a rival product. We can now capitalize on this patent to accelerate JAZZ’s transformation into a technological platform comprising a comprehensive range of implants covering 100% of our market. Our highly-promising portfolio of innovations will enable us to rapidly meet the demands of the entire spine surgeon community.”
Contacts
Florent ALBA
NewCap
Investor Relations & Strategic Communication
21 Place de la Madeleine – 75008 Paris – France
Tel: +33 1 44 71 98 55
Nicolas Merigeau
NewCap
Media Relations
21 Place de la Madeleine – 75008 Paris – France
Tel: +33 1 44 71 94 98